Showing 1111-1120 of 2942 results for "".
- News Briefshttps://practicalneurology.com/columns/practice-management/news-briefs/31400/Recent advancements in Alzheimer’s disease (AD) research are shedding light on its elusive etiology and pathophysiology, offering new insights for healthcare professionals. A significant study published in the *American Journal of Industrial Medicine* analyzed 2.6 million death records from 22 state
MS Minute: Oral Therapies for MS
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/ms-minute-oral-therapies-for-ms/31607/The advent of oral therapies has ushered in a new phase of disease-modifying treatments.Understanding Disparities Associated with Alzheimer Disease and Related Dementias
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/understanding-disparities-associated-with-alzheimer-disease-and-related-dementias/32142/Clinicians need to take into consideration a variety of factors resulting in disparities in health outcomes in people with dementia, including socioeconomic status, race, ethnicity, environment, life experiences, and culture.Disparities in Alzheimer Disease and Alzheimer-Related Dementias: Considerations for Clinical Decision-Making and Treatment
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/disparities-in-alzheimer-disease-and-alzheimer-related-dementias-considerations-for-clinical-decision-making-and-treatment/32016/Taking into account social determinants of health and identifying solutions to improve patient care.Pharmacologic Management of Behavioral Challenges and Psychiatric Comorbidities in People With Epilepsy
https://practicalneurology.com/diseases-diagnoses/epilepsy-seizures/pharmacologic-management-of-behavioral-challenges-and-psychiatric-comorbidities-in-people-with-epilepsy/39969/Treatment of behavioral and psychiatric comorbidities in people with epilepsy requires careful consideration of underlying causes, symptom profile, antiseizure medications, and epilepsy type.Headache Medicine Update: What’s New in CGRP Functional Blocking Agents
https://practicalneurology.com/diseases-diagnoses/headache-pain/headache-medicine-update-whats-new-in-cgrp-functional-blocking-agents/32126/CGRP blocking agents have demonstrated success in migraine treatment and can be used in various settings, in different combinations, and for different headache conditions.Updates in Bruton Tyrosine Kinase Inhibition for Multiple Sclerosis
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/updates-in-bruton-tyrosine-kinase-inhibition-for-multiple-sclerosis/31975/Ongoing clinical trials will elucidate potential advantages and safety of these novel medications for future treatment of multiple sclerosis.Neurologic Manifestations & Associations of COVID-19
https://practicalneurology.com/diseases-diagnoses/imaging-testing/neurologic-manifestations-associations-of-covid-19/31739/High-quality epidemiologic data is still urgently needed to better understand neurologic effects of COVID-19.Point/Counterpoint: Neurofilament Light
https://practicalneurology.com/diseases-diagnoses/imaging-testing/pointcounterpoint-neurofilament-light/31628/Ready for prime time as a biomarker for multiple sclerosis or not?Relapse Management in Multiple Sclerosis: Corticosteroids Remain the Linchpin of Therapies
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/relapse-management-in-multiple-sclerosis-corticosteroids-remain-the-linchpin-of-therapies/32084/Several modalities are available for the treatment of multiple sclerosis relapse, including corticosteroids, intravenous immunoglobulins, and therapeutic apheresis.